ADRIM has a wide spectrum of antineoplastic activity. It has been used successfully to produce regression in many neoplastic conditions like acute lymphoblastic and myeloblastic leukemias, malignant lymphomas of both Hodgkin's and Non Hodgkin's type, carcinoma of the breast, lung, bladder, gastric, thyroid as well as ovarian carcinoma, bone and soft tissue sarcomas, neuroblastoma and Wilm's tumour. The drug has also demonstrated activity in carcinoma of endometrium, testes, prostate and cervix.
DOSAGE FORMS AND PACKAGING AVAILABLE:
ADRIM is available as 5ml and 25ml vial containing 10mg and 50mg of Doxorubicin Hydrochloride, respectively, as a ready to use solution.